Dysferlinopathy results from qualitative or quantitative defects of the dysferlin protein, as reflected in the disease's clinical designation. The packet's known_genes field contains no gene symbol entries; gene-level specifics are drawn from the GeneReviews chapter. The GeneReviews genetic counseling section states that dysferlinopathy is inherited in an autosomal recessive manner, meaning two pathogenic alleles are required for disease expression. Heterozygous carriers are described by GeneReviews as asymptomatic and not at risk of developing the disorder. All four clinical subtypes — MMD, LGMD2B, distal myopathy with anterior tibial onset, and asymptomatic hyperCKemia — can occur within the same family carrying identical pathogenic variants, indicating that subtype expression is not strictly determined by genotype. GeneReviews documents population-specific founder variants: a prevalence of at least 1:1,300 with approximately 10% carrier rate in Libyan Jews; a founder variant identified in Jews from the Caucasus; and a separate founder variant identified in individuals from Spain.

GeneReviews states that no consensus clinical diagnostic criteria for dysferlinopathy have been published, and the packet's diagnostic_methods field contains no entries. Each major phenotype has characteristic suggestive findings described in GeneReviews. For Miyoshi muscular dystrophy: mid-to-late childhood or early-adult onset (GeneReviews reports mean 19.0 years), early and predominant distal muscle weakness affecting the calf muscles, slow progression, serum CK elevation often 10–100 times normal (mean CK 8,940 IU/L), and a primarily myogenic pattern on electromyography. For LGMD2B: predominant early weakness and atrophy of the pelvic and shoulder girdle muscles with onset typically in the late teens or later, slow progression, massive serum CK elevation, and subclinical distal muscle involvement identifiable by muscle CT or MRI. The minor phenotypes — asymptomatic hyperCKemia and DMAT — are considered in individuals presenting with marked isolated CK elevation or anterior compartment lower limb weakness, respectively. GeneReviews notes that a family history consistent with autosomal recessive inheritance may inform diagnostic consideration.

GeneReviews states that no approved therapy exists for dysferlinopathy and that treatment is symptomatic. No drugs appear in the packet's approved_treatments or foundational_therapies fields, and the packet's orphan_drugs field contains no entries. Supportive approaches documented in GeneReviews management guidance include physical therapy and rehabilitation medicine for musculoskeletal involvement, encompassing ambulatory assistive device planning, stretching exercises, and physical activity programming. Orthopedic surgery is noted for complications such as foot deformity and scoliosis. Occupational therapy addresses activities of daily living, including transfers, adaptive devices, and household modifications. Respiratory function is addressed in nonambulatory individuals. GeneReviews identifies circumstances noted as associated with adverse outcomes in dysferlinopathy: weight-related obesity and the use of steroids are described in the agents-to-avoid section of GeneReviews management guidance.

GeneReviews provides mobility trajectory data across phenotypes. For MMD, mean age at cane requirement is approximately 35.5 years (approximately 16 years after mean onset), and mean age at wheelchair dependence is approximately 42.8 years (approximately 22.8 years after onset). For LGMD2B, mean cane requirement occurs at approximately 39.3 years and wheelchair dependence at approximately 45.1 years. Median serum CK levels vary across subtypes: approximately 4,440 IU/L in MMD, approximately 3,481 IU/L in LGMD2B, approximately 7,156 IU/L in asymptomatic hyperCKemia, and approximately 1,000 IU/L in DMAT. Cardiac complications occur in approximately 3.6% of MMD cases. GeneReviews management guidance states that appropriate supportive care can prolong survival and improve quality of life. The packet's natural_history field contains no data.

The packet records 1 active clinical trial in ClinicalTrials.gov for this condition; no detailed trial records are provided in the current packet. GeneReviews identifies several investigational approaches. Vamorolone is being compared with prednisolone on dysferlin-deficient myofiber repair; GeneReviews reports that vamorolone stabilized dysferlin-deficient muscle cell membranes and improved repair of dysferlin-deficient mouse myofibers in preclinical work. Antisense oligonucleotide-mediated exon skipping has been designed to bypass the effect of specific pathogenic variants on RNA splicing, with GeneReviews citing in vitro evidence of restored normal mRNA production and significant dysferlin protein expression recovery. AMP-activated protein kinase (AMPK) pathway activation is described by GeneReviews as rescuing membrane-repair impairment observed in immortalized human myotubes with reduced dysferlin expression. The Jain Foundation maintains a patient registry that supports ongoing research activity.